MissionIR Articles
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference
QSAM Biosciences (OTCQB: QSAM) is developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced that it has been invited to present at…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases, today announced financial results for the third quarter ended Sept. 30, 2022, and…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has added Rutgers Cancer Institute of New Jersey (“RCINJ”) as a clinical…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Working to Make a Difference in Underserved Patient Populations
QSAM Biosciences (OTCQB: QSAM) is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric population. “With the overall incidence of…
-
QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals
Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)
QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update
QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June…
-
QSAM Biosciences Inc. (QSAM) Awarded Patent for Potential Breakthrough Bone Cancer Treatment
This is the third U.S. patent granted to QSAM, further strengthening its IP portfolio, which consists of 14 patents among three patent families. “CycloSam has potential to be a breakthrough therapy for both primary and…
-
MissionIRNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)
QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking…
-
MissionIRNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’
QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective…
-
QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial
Treating patients with primary or secondary bone cancer remains goal, says company CEO Radiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cells QSAM is working to develop CycloSam(R) as a…
-
QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’
QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone…
Search Articles
Latest Articles
- MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures Second Juvenile Probation EM Contract in Texas
- MissionIRNewsBreaks – GridAI Technologies Corp. (NASDAQ: GRDX) and the Quiet Shift That Makes Electricity the Next AI Bottleneck
- MissionIRNewsBreaks – A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Expands Into Toy Retail With Smart Cart Orders From Toys “R” Us Israel and The Red Pirate
- MissionIRNewsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Highlights 2025 Milestones Advancing DropAir Precision Airdrop System
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) to Showcase NIJ 0101.07 Certification-Ready Body Armor Plates and RAPID Series Ballistic Shield at SHOT Show 2026